Nova Biomedical introduces PAIA Titer technology for earlier cell line development insights
New assay capabilities on the VIPS PRO and Cell Metric X platforms provide productivity and product quality data earlier in cell line development, helping scientists advance the most promising clones sooner
22 Oct 2026
Nova Biomedical has announced the integration of PAIA Titer assay technology into its cell line development portfolio, enabling scientists to use the VIPS® PRO and Cell Metric® X platforms to assess productivity and product quality earlier in cell line development to make more informed decisions about which clones to advance.
Cell line development requires scientists to evaluate large numbers of potential clones while balancing multiple critical characteristics, including clonality, growth, productivity and product quality.
Traditionally, valuable productivity and quality information can arrive later in the workflow, after significant time and resources have already been invested in expanding candidate clones.
The technology complements Nova Biomedical's broader integrated assay capabilities, which include titer, cell counting and viability, and glycan analysis to support productivity and product quality assessment during cell line development.
From single cell to high-value clone
PAIA Titer is designed to integrate productivity data into a connected cell line development workflow rather than serving as a standalone endpoint measurement. “Cell line development is ultimately about making the right decisions earlier," said John Luck, president of Nova Biomedical's Biopharma business.
"By bringing productivity and product quality data forward in the workflow, PAIA Titer enables scientists to identify the clones with the greatest potential sooner and focus their time and resources where they matter most. Its integration with the VIPS PRO and Cell Metric X platforms is another important step toward connecting the data scientists use to move from a single cell to a high-value clone.”
At the front of the cell line development workflow, the NanoCellect® WOLF G2® cell sorter enables scientists to enrich selected cell populations and gently isolate viable cells using low-pressure microfluidic sorting.
The VIPS PRO integrated single-cell cloning platform combines gentle nanodroplet single-cell seeding, AI-assisted cell detection, integrated imaging, clonality assurance and assay capabilities. This enables teams to progress from single-cell deposition through clone assessment and selection without relying on multiple disconnected systems.
The VIPS PRO platform’s double-lock clonality assurance combines nanodroplet and whole-well imaging to support image-based clonality evidence from day 0, while integrated assay workflows add productivity and product quality information to the clone selection process.
PAIA Titer technology is also integrated with Nova Biomedical's scalable Cell Metric X imaging and automation platform for high-throughput clonality assurance and clone growth monitoring. Cell Metric X combines high-resolution, multi-plane whole-well imaging, AI-assisted image analysis and scalable automation, supporting workflows from standalone imaging to fully integrated robotic environments.
Together, PAIA Titer, VIPS PRO and Cell Metric X connect clonality, growth and productivity data earlier in cell line development, helping scientists make more informed clone selection decisions.
Want the latest science news straight to your inbox? Become a SelectScience member for free today>>
Links
Tags
Frequently asked questions
Show frequently asked questions
How does Nova Biomedical’s PAIA Titer technology improve cell line development?
PAIA Titer brings productivity and product quality data earlier into the cell line development workflow. Integrated with the VIPS® PRO and Cell Metric® X platforms, it helps scientists identify promising clones sooner and make informed decisions before investing significant time and resources in clone expansion.
What capabilities does the Nova Biomedical VIPS PRO platform provide?
VIPS PRO combines gentle nanodroplet single-cell seeding, AI-assisted cell detection, integrated imaging, clonality assurance, and assay capabilities. Its double-lock clonality assurance uses nanodroplet and whole-well imaging to provide image-based clonality evidence from day 0 while supporting productivity and product quality assessment.
How does Cell Metric X support high-throughput clone selection and clonality assurance?
Cell Metric X integrates PAIA Titer with high-resolution, multi-plane whole-well imaging, AI-assisted image analysis, and scalable automation. It supports high-throughput clonality assurance and clone growth monitoring in workflows ranging from standalone imaging to fully integrated robotic environments.